Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biovest to seek early approval of lymphoma vaccine
Subject to the completion of the anticipated analysis of the unblinded trial data, the company plans to seek accelerated conditional approval for BiovaxID in the US, Europe and
Subject to the completion of the anticipated analysis of the unblinded trial data, the company plans to seek accelerated conditional approval for BiovaxID in the US, Europe and
The trial began in patients with locally advanced or metastatic cancers that are refractory to standard therapy or for whom no standard therapies exist. The primary objectives of
The study met its primary endpoint, demonstrating less venous procedural pain in those treated with Zingo powder intradermal injection system compared to placebo. Patients received zingo or placebo
Triolex acts by modulating the anti-inflammatory pathway NF-kappaB. The trial is a 28-day study designed to evaluate the safety of the drug candidate and determine the optimal dose
Exelixis is continuing to analyze the data to assess whether further evaluation of the compound is warranted. The results of the potent small molecule inhibitor, XL784 meet the
The Lovaxin C vaccine, being developed by biotechnology company Advaxis, is intended to treat cervical cancer and head and neck cancers that result from the human papilloma virus.
The multinational trial, which will evaluate once daily oral forodesine HCL treatment, will be conducted in accordance with a special protocol assessment agreement between the FDA and BioCryst
The purpose of the trial is to examine the effectiveness of Zyflo at reducing the length of a hospital stay for adults who are hospitalized for a chronic
Elvucitabine is an L-cytosine nucleoside analog reverse transcriptase inhibitor that has previously demonstrated potent antiviral activity against HIV, including strains resistant to other NRTIs. The objectives of the
During the meeting with the FDA, male sexuality was mutually determined not to be appropriate as a clinical endpoint. As a result of the meeting, Repros plans to